Renal denervation in treatment-resistant hypertension: a reappraisal

Area of Science:

• Cardiology
• Nephrology
• Hypertension Management

Background:

• Resistant hypertension poses a significant clinical challenge.
• Renal denervation (RDN) emerged as a potential therapeutic option following promising early studies (Symplicity HTN-1 and 2).
• Significant enthusiasm surrounded RDN's potential for blood pressure reduction.

Purpose of the Study:

• To evaluate the efficacy and safety of renal denervation (RDN) in patients with resistant hypertension.
• To assess the impact of RDN on systolic blood pressure reduction compared to sham procedures.
• To determine if RDN is a viable clinical application for managing resistant hypertension.

Main Methods:

• The study employed a sound methodology to investigate the effectiveness of RDN.
• A large-scale clinical trial (Symplicity HTN-3) was conducted to assess RDN's primary efficacy endpoint.
• Control groups and rigorous statistical analysis were utilized to evaluate outcomes.

Main Results:

• The Symplicity HTN-3 trial failed to meet its primary efficacy endpoint.
• The expected significant systolic blood pressure decrease (25-30mmHg) following RDN was not observed, with changes <3mmHg.
• The results contrasted sharply with the initial enthusiasm generated by earlier RDN studies.

Conclusions:

• Renal denervation (RDN) is not currently ready for wide clinical application in treating resistant hypertension.
• RDN warrants further investigation to understand its role and optimize its application.
• Current focus should remain on improving medication adherence and optimizing pharmacological treatment for hypertensive patients.